The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 40 | — | 20.1x | Near average | |
Growth | 6 | -36.2% | 5.6% | Below average | |
Quality | 34 | -295.0% | 7.6% | Below average | |
Safety | 30 | 0.1x | 0.4x | Below average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Nektar Therapeutics is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Nektar Therapeutics shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Nektar Therapeutics (NKTR) has seen a positive revision in its Consensus price target over the last 30 days, rising from 144.83 to 149.6, an increase of 3.29%. This adjustment comes despite the number of analysts remaining steady at 4, indicating that one of the current analysts raised their individual estimates based on new data, rather than the entry of new market opinions. The current price of the stock (66.61) is trading at a significant discount below the lowest price target (80), reflecting a wide valuation gap.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.